Advanced Therapies Week 2027: What to Know About the Cell and Gene Therapy Industry's Biggest Partnering Event

Advanced Therapies Week, the annual industry and partnering conference organized by Phacilitate, returns January 18–21, 2027, at the San Diego Convention Center. Now in its 22nd year, the event has grown into one of the largest gatherings dedicated specifically to the business and manufacturing side of cell and gene therapy — a useful point of reference for readers who want to understand where the regenerative medicine field is headed commercially and regulatorily, separate from any individual clinic's marketing claims.

What the Event Is

Advanced Therapies Week bills itself as the "premier biotech partnering event" in the United States for cell and gene therapy. Unlike scientific society meetings such as ISSCR or ASGCT, which are built around peer-reviewed research presentations, Advanced Therapies Week is structured around deal-making, manufacturing logistics, and commercialization strategy. It draws developers, contract manufacturers, suppliers, regulators, and investors into one venue over four days, with an exhibition hall for tools and technology vendors alongside the conference sessions.

Why the Shift to San Diego Matters

The conference has been held in Miami Beach and Orlando in past years; moving to San Diego for 2027 places it in one of the country's most concentrated biotech manufacturing and life sciences hubs. For an industry still working out how to scale cell and gene therapy production beyond small, artisanal batch processes, hosting the event near a dense cluster of manufacturing partners and CDMOs (contract development and manufacturing organizations) is a notable logistical and signaling choice.

What's on the Agenda

Based on prior years' programming and the event's own stated focus areas, Advanced Therapies Week typically covers manufacturing scale-up and automation, vector and gene-delivery innovation, supply chain resilience, global regulatory harmonization, early-stage therapeutic development, and investment and commercialization pathways. These are the unglamorous but essential problems standing between a promising cell or gene therapy in a lab and a treatment that's actually accessible and affordable to patients — exactly the kind of structural detail that tends to get skipped over in consumer-facing stem cell marketing.

Who Attends

The event has historically drawn roughly 2,000 industry professionals, more than 250 international speakers, and around 200 exhibiting companies, spanning therapeutic developers, academic researchers, regulators, and manufacturing and logistics vendors. It is an industry and B2B conference rather than a venue for patients or the public, and registration is generally aimed at professionals working in the field.

How Readers Can Learn More

Readers interested in tracking announcements, regulatory discussions, or manufacturing developments that come out of the conference can watch for coverage from trade press and the event's own site (phacilitate.com) in the lead-up to January 2027. As always, any therapy or manufacturing claim tied to the conference should be weighed against peer-reviewed evidence and regulatory status, not treated as validation on its own.

Bottom Line

Advanced Therapies Week 2027 is a significant industry touchpoint for understanding how cell and gene therapies move from the lab toward real-world manufacturing and patient access — but it is a trade and partnering event, not a clinical evidence source. Readers evaluating any specific stem cell or gene therapy should still look to peer-reviewed data and regulatory status (e.g., FDA approval or active clinical trial registration) rather than conference buzz.